
    
      PHAGOBURN is a Phase I/II clinical trial randomized, multicentric, open label, standard of
      care (Silver Sulfadiazine) controlled aiming at assessing tolerance and efficacy of local
      bacteriophage treatment of wound infections due to E. coli or P. aeruginosa in burned
      patients using Pherecydes Pharma anti-Escherichia coli and anti-Pseudomonas aeruginosa
      bacteriophage cocktails GMP produced. This project is a European Research & Development (R&D)
      project funded by the European Commission under the 7th Framework Programme for Research and
      Development. This project is involving 7 clinical sites in EU.
    
  